International expert consensus recommendations for the use of dermatocosmetics in acne
https://doi.org/10.33667/2078-5631-2025-23-13-18
Abstract
Background. Dermatocosmetics containing active ingredients that reduce the severity of the disease symptoms play an important role in the skin care of patients suffering from acne. They are used independently and in combination with drug therapy, improving its tolerability and results. Basic care includes cleansing, moisturizing, and sunscreen products.
Methods. An international group of experts of dermatology with experience in the treatment of acne conducted a literature review and formulated questions regarding the impact of dermatocosmetics on the course of the disease, both independently and in combination with drug treatments. Based on the literature data and their own experience, the experts answered the questions and formulated recommendations for the use of dermatocosmetics in the treatment of acne.
Results. The experts confirmed that dermatocosmetics improve the course of the disease in mild cases, reduce the number of rashes, reduce skin oiliness, and are well tolerated by patients. In combination with medical treatment – improves the results of the latter, its tolerability, increases the compliance of treatment. The important role of dermatocosmetics in the prevention and elimination of post‑inflammatory hyperpigmentation is noted.
Conclusion. Despite the low quality of evidence associated with a limited number of studies, dermatocosmetics has shown effectiveness when used independently for mild acne and adjunct to drug treatment.
About the Author
A. N. Khlebnikova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Khlebnikova Albina N., DM Sci (habil.), professor, professor at Dept of Dermatovenereology and Dermato-Oncology, Faculty of Advanced Medical Studies
Moscow
References
1. Heng A.H.S., Chew F.T. Systematic review of the epidemiology of acne vulgaris. Sci Rep 2020; 10 (1): 5754. DOI: 10.1038/s41598 020 62715 3.
2. Vasam M., Korutla S., Bohara R.A. Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances. Biochemistry and Biophysics Reports 2023; 36: 101578. DOI: 10.1016/j.bbrep.2023.101578
3. Marson J., Bhatia N., Graber E., Harper J., Lio P., Tlougan B., Nussbaum D., Baldwin H. The Role of Epidermal Barrier Dysfunction and Cutaneous Microbiome Dysbiosis in the Pathogenesis and Management of Acne Vulgaris and Rosacea. J Drugs Dermatol. 2022; 21:9 (Suppl 2): s5–14. DOI: 10.36849/JDD.m0922.
4. Thiboutot D., Layton A.M., Traore I., Gontijo G., Troielli P., Ju Q., Kurokawa I., Dreno B. International expert consensus recommendations for the use of dermocosmetics in acne. J Eur Acad Dermatol Venereol. 2024; 00: 1–15. doiI: 10.1111/jdv.20145
5. Araviiskaia E, Dreno B. The role of topical dermocosmetics in acne vulgaris. J Eur Acad Dermatol Venereol. 2016; 30: 926–935. DOI: 10.1111/jdv.13579.
6. Saint Leger D. ‘Cosmeceuticals’. Of men, science and laws. Int J Cosmet Sci 2012; 34 (5): 396–401. DOI: 10.1111/j.1468–2494.2012.00740.x
7. Araviiskaia E, Lopez Estebaranz JL, Pincelli C. Dermocosmetics: beneficial adjuncts in the treatment of acne vulgaris. J Dermatolog Treat. 2021; 32: 3–10. DOI: 10.1080/09546634.2019.1628173.
8. Dreno D., Dagnelie M.A., Khammari A., Corvec S. The Skin Microbiome: A New Actor in Inflammatory Acne. American Journal of Clinical Dermatology 2020; 21 (Suppl 1): S18–S24. DOI: 10.1007/s40257 020 00531 1.
9. Dagnelie M A, Corvec S, Timon David E, Khammari A, Dréno B. Cutibacterium acnes and Staphylococcus epidermidis: the unmissable modulators of skin inflammatory response. Exp Dermatol. 2022; 31: 406–412. DOI: 10.1111/exd.14467
10. Lain E, Andriessen AE. Choosing the right partner: complementing prescription acne medication with over the counter cleansers and moisturizers. J Drugs Dermatol. 2020; 19 (11): 1069–1075. DOI: 10.36849/JDD.2020.5536.
11. Hwang B.K., Lee S., Myoung J., Hwang S.J., Lim J.M,, Jeong E.T., Park S.G., Youn S.H. Effect of the skincare product on facial skin microbial structure and biophysical parameters: a pilot study. Microbiology Open. 2021; 10: e1236. DOI: 10.1002/mbo3.1236
12. Shahmoradi Z, Iraji F, Siadat AH, Ghorbaini A. Comparison of topical 5% nicotinamide gel versus 2% clindamycin gel in the treatment of the mild moderate acne vulgaris: a double blinded randomized clinical trial. J Res Med Sci. 2013; 18: 115–117.
13. Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ER. Topical 4 % nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. Int J Dermatol. 2013; 52: 999 1004. DOI: 10.1111/ijd.12002.
14. Yoon JY, Kwon HH, Min SU, Thiboutot DM, Suh DH. Epigallocatechin 3 gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J Invest Dermatol. 2013; 133: 429–440. DOI: 10.1038/jid.2012.292.
15. Villani A, Annunziata MC, Cinelli E, Donnarumma M, Milani M, Fabbrocini G. Efficacy and safety of a new topical gel formulation containing retinol encapsulated in glycospheres and hydroxypinacolone retinoate, an antimicrobial peptide, salicylic acid, glycolic acid and niacinamide for the treatment of mild acne: preliminary results of a 2 month prospective study. G Ital Dermatol Venereol. 2020; 155: 676–679. Doi: 10.23736/S0392–0488.20.06581–5.
16. Kozan A, Guner RY, Akyol M. A retrospective assessment and comparisonof the effectiveness of benzoyl peroxide; the combination oftopical niacinamide, gallic acid, and lauric acid; and the combination of benzoyl peroxide and erythromycin in acne vulgaris. Dermatol Ther. 2020; 33: e13534. DOI: 10.1111/dth.13534.
17. Li W, Yu Q, Shen Z, Zhang L, Zhang W, Li C. The efficacy and safety of a cream containing octyl salicylic acid, salicylic acid, linoleic acid, nicotinamide and piroctone olamine combined with 5% benzoyl peroxide in the treatment of acne vulgaris: a randomized controlled study. Chin Med J. 2022; 135: 1381–1382. Doi: 10.1097/CM9.0000000000002191.
18. Dal Belo SE, Kanoun Copy L, Lambert C, Cornillon C, Muller B, Jouni H, et al. Efficacy of a multitargeted, salicylic acid-based dermocosmetic cream compared to benzoyl peroxide 5% in acne vulgaris: results from a randomized study. J Cosmet Dermatol. 2024; 23: 891–897. DOI: 10.1111/jocd.16052. Epub 2023
19. Zheng Y, Yin S, Xia Y, Chen J, Ye C, Zeng Q,, Lai W. Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/ 0.1% adapalene in the acne treatment: a randomized, split face, open label, single center study. Cutan Ocul Toxicol. 2019; 38: 48–54. DOI: 10.1080/15569527.2018.1518329.
20. Wongtada C, Prombutara P, Asawanonda P, Noppakun N, Kumtornrut C, Chatsuwan T. Distinct skin microbiome modulation following different topical acne treatments in mild acne vulgaris patients: a randomized, investigator blindedexploratory study. Exp Dermatol. 2023; 32: 906–914. DOI: 10.1111/exd.14779.
21. Capitanio B, Sinagra JL, Weller RB, Brown C, Berardesca E. Randomized controlled study of a cosmetic treatment for mild acne. Clin Exp Dermatol. 2012; 37: 346–349. DOI: 10.1111/j.1365–2230.2011.04317.x.
22. Fabbrocini G, Panariello L. Efficacy and tolerability of a topical gel containing 3% hydrogen peroxide, 1.5 % salicylic acid and 4 % D panthenol in the treatment of mild moderate acne. G Ital Dermatol Venereol. 2016;151:287–291.
23. Kulthanan K, Trakanwittayarak S, Tuchinda PC, Chularojanamontri L, Limphoka P, Varothai S. A double blinded, randomized, vehicle controlled study of the efficacy of moisturizer containing licochalconea, decanediol, L-carnitine, and salicylic acid for prevention of acne relapse in Asian population. Biomed Res Int. 2020; 2857812. DOI: 10.1155/2020/2857812.
24. Bettoli V, Zauli S, Borghi A, Toni G, Ricci M, Bertoldi AM, Virgil A. Efficacy and safety of a 12 month treatment with a combination of hydroxypinacolone retinoate and retinol glycospheres as maintenance therapy in acne patients after oral isotretinoin. G Ital Dermatol Venereol. 2017; 152: 13–17. DOI: 10.23736/S0392–0488.16.05201–9.
25. Queille Roussel C, LeFloc’h C, Le Dantec G, Cathelineau AC, Dreno B, Kerob D. Ultraconcentrated tri acid complex serum as maintenance therapy in adult female acne. J Eur Acad Dermatol Venereol. 2023; 37: e840–e841. DOI: 10.1111/jdv.18909.
26. Chularojanamontri L, Tuchinda P, Kulthanan K, Varothai S, Winayanuwattikun W. A double-blinded, randomized, vehicle-controlled study to access skin tolerability and efficacy of an anti inflammatory moisturizer in treatment of acne with 0.1% adapalene gel. J Dermatolog Treat. 2016; 27: 140–145. DOI: 10.3109/09546634.2015.1079298.
27. Cannizzaro MV, Dattola A, Garofalo V, del Duca E, Bianchi L. Reducing the oral isotretinoin skin side effects: efficacy of 8% omega ceramides, hydrophilic sugars, 5% niacinamide cream compound in acne patients. G Ital Dermatol Venereol. 2018; 153: 161–164 DOI: 10.23736/S0392–0488.17.05742 X.
28. Del Rosso JQ, Gold M, Rueda MJ, Brandt S, Winkelman WJ. Efficacy, safety, and subject satisfaction of a specified skin care regimen to cleanse, medicate, moisturize, and protect the skin of patients under treatment for acne vulgaris. J Clin Aesthet Dermatol. 2015; 8: 22–30.
29. Karamon E, Czermańska A, Kerob D, Demessant AL, Le Dantec G, le Floc’h C, Tan J. Benefits of a dermocosmetic regimen in the management of local side effects triggered by a topical retinoid based acne treatment. J Cosmet Dermatol. 2024 Mar; 23 (3): 1091–1093. DOI: 10.1111/jocd.16055
30. Monfrecola G, Capasso C, Russo G, Fabbrocini G. UV selective face cream (Acne RA 1,2) in acne patients: clinical study of its effects on epidermal barrier function, sebum production, tolerability and therapy adherence. G Ital Dermatol Venereol. 2018; 153: 26–32. DOI: 10.23736/S0392–0488.16.05384–0
31. Chularojanamontri L, Tuchinda P, Kulthanan K, Varothai S, Winayanuwattikun W. A double-blinded, randomized, vehicle-controlled study to access skin tolerability and efficacy of an anti inflammatory moisturizer in treatment of acne with 0.1% adapalene gel. J Dermatolog Treat. 2016; 27: 140–145. DOI: 10.3109/09546634.2015.1079298.
32. Polakova K, Fauger A, Sayag M, Jourdan E. A dermocosmetic containing bakuchiol, Ginkgo biloba extract and mannitol improves the efficacy of adapalene in patients with acne vulgaris: result from a controlled randomized trial. Clin Cosmet Investig Dermatol. 2015; 8: 187–191. DOI: 10.2147/CCID.S81691
33. Kantikosum K, Chongpison Y, Chottawornsak N, Asawanonda P. The efficacy of glycolic acid, salicylic acid, gluconolactone, and licochalcone a combined with 0.1% adapalene vs adapalene monotherapy in mild to Moderate acne vulgaris: a double blinded within person comparative study. Clin Cosmet Investig Dermatol. 2019; 12: 151–161. DOI: 10.2147/CCID.S193730.
34. Abad Casintahan F, Chow SK, Goh CL, Kubba R, Hayashi N, Noppakun N, et al. Frequency and characteristics of acne related post inflammatory hyperpigmentation. J Dermatol. 2016; 43: 826–828. DOI: 10.1111/1346–8138.13263.
35. DuBois J, Ong GCW, Petkar G, Almeida LMC, Chavda R, Kerrouche N, et al. Patient reported outcomes in acne patients with skin of color using adapalene 0.3% benzoyl peroxide 2.5%: a prospective real world study. J Drugs Dermatol. 2019; 18: 514–520
36. Brito S, Baek JM, Cha B, Heo H, Lee SH, Lei L, et al. Nicotinamide mononucleotide reduces melanin production in aged melanocytes by inhibiting cAMP/Wnt signaling. J Dermatol Sci. 2022; 106: 159–169. DOI: 10.1016/j.jdermsci.2022.05.002
Review
For citations:
Khlebnikova A.N. International expert consensus recommendations for the use of dermatocosmetics in acne. Medical alphabet. 2025;1(23):13-18. (In Russ.) https://doi.org/10.33667/2078-5631-2025-23-13-18
Views:
17
Email this article 